Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
ZNTL Analyst Ratings
Moderate Buy
4 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ZNTL Stock 12 Month Forecast
Average Price Target
$6.71
▲(290.12% Upside)
| Highest Price Target$10.00 | Average Price Target$6.71 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10
Buy
481.40%
Upside
Reiterated
10/27/25
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis PharmaceuticalsValuation and risk to achievement of price target. Our price target of $10 is based on an equally-weighted composite of: (a) $11.06/share, as a 20x multiple of taxed and diluted $1.53 discounted back to 12/31/25 at 12% (in line with the expected P/E multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $9.2/share (discounted cash flow analysis using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, competition, manufacturing, financial, liability and intellectual property risks.
Leerink Partners
$5
Hold
190.70%
Upside
Reiterated
08/07/25
Morgan Stanley
$8
Hold
365.12%
Upside
Reiterated
08/07/25
Wedbush
$4
Hold
132.56%
Upside
Reiterated
08/07/25
Oppenheimer
$9
Buy
423.26%
Upside
Reiterated
08/07/25
Guggenheim
$6
Buy
248.84%
Upside
Reiterated
08/06/25
Wells Fargo
$6→$5
Hold
190.70%
Upside
Reiterated
08/06/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
Jefferies
$6→$2.5
Hold
45.35%
Upside
Reiterated
01/29/25
UBS
$5→$2.2
Hold
27.91%
Upside
Reiterated
01/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10
Buy
481.40%
Upside
Reiterated
10/27/25
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis PharmaceuticalsValuation and risk to achievement of price target. Our price target of $10 is based on an equally-weighted composite of: (a) $11.06/share, as a 20x multiple of taxed and diluted $1.53 discounted back to 12/31/25 at 12% (in line with the expected P/E multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $9.2/share (discounted cash flow analysis using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, competition, manufacturing, financial, liability and intellectual property risks.
Leerink Partners
$5
Hold
190.70%
Upside
Reiterated
08/07/25
Morgan Stanley
$8
Hold
365.12%
Upside
Reiterated
08/07/25
Wedbush
$4
Hold
132.56%
Upside
Reiterated
08/07/25
Oppenheimer
$9
Buy
423.26%
Upside
Reiterated
08/07/25
Guggenheim
$6
Buy
248.84%
Upside
Reiterated
08/06/25
Wells Fargo
$6→$5
Hold
190.70%
Upside
Reiterated
08/06/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
Jefferies
$6→$2.5
Hold
45.35%
Upside
Reiterated
01/29/25
UBS
$5→$2.2
Hold
27.91%
Upside
Reiterated
01/28/25
Best Analysts Covering Zentalis Pharmaceuticals
1 Month
xxx
Success Rate
4/10 ratings generated profit
Average Return
-3.73%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -3.73% per trade.
3 Months
xxx
Success Rate
9/18 ratings generated profit
Average Return
-7.16%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -7.16% per trade.
1 Year
Success Rate
3/10 ratings generated profit
Average Return
-22.84%
reiterated a buy rating 3 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -22.84% per trade.
2 Years
xxx
Success Rate
2/10 ratings generated profit
Average Return
-37.82%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -37.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ZNTL Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
9
9
4
7
5
Buy
1
2
1
2
1
Hold
12
10
6
8
4
Sell
5
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
21
11
17
10
Each month's total comprises the sum of three months' worth of ratings.
ZNTL Financial Forecast
ZNTL Stock Forecast FAQ
What is ZNTL’s average 12-month price target, according to analysts?
Based on analyst ratings, Zentalis Pharmaceuticals’s 12-month average price target is 6.71.
What is ZNTL’s upside potential, based on the analysts’ average price target?
Zentalis Pharmaceuticals has 290.12% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ZNTL a Buy, Sell or Hold?
Zentalis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.
What is Zentalis Pharmaceuticals’s price target?
The average price target for Zentalis Pharmaceuticals is 6.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 290.12% Increase from the current price of $1.72.
The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 290.12% Increase from the current price of $1.72.
What do analysts say about Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ZNTL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.